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Abstract
Background: Patients on continuous ambulatory peritoneal dialysis (PD) are encouraged to warm dialysate to 37 °C
before peritoneal infusion; main international PD guidelines do not provide specific recommendation, and patients
generally warm dialysate batches partially or do not warm them at all. Warming of dialysate is a time-consuming
procedure, not free from potential risks (i.e. degradation of glucose), and should be justified by a clear clinical
benefit.
Methods: We designed a single blind randomized controlled trial where 18 stable PD patients were randomized to
receive a peritoneal equilibration test either with dialysate at a controlled temperature of 37 °C (intervention group)
or with dialysate warmed with conventional methods (control group). Primary end-point was a higher peritoneal
creatinine clearance in patients in the intervention group.
Results: Patients in the intervention group did not show a significantly higher peritoneal creatinine clearance when
compared to the control group (6.38 ± 0.52 ml/min vs 5.65 ± 0.37 ml/min, p = 0.2682). Similar results were obtained
for urea peritoneal clearance, mass transfer area coefficient of creatinine and urea. There were no significant
differences in total abdominal discomfort questionnaire score, blood pressure and body temperature between the
two groups.
Conclusions: Using peritoneal dialysate at different temperatures without causing significant side effects to patients
appears feasible. We report a lack of benefit of warming peritoneal dialysate to 37 °C on peritoneal clearances;
future PD guidelines should not reinforce this recommendation.
Trial registration: NCT04302649, ClinicalTrials.gov; date of registration 10/3/2020 (retrospectively registered).
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Background
Peritoneal dialysis (PD) currently represents the main
choice for home renal replacement treatment for pa-
tients with end stage renal disease. One of the limita-
tions of PD technique is represented by the difficulty in
achieving target dialytic clearances and PD adequacy for
some patients, especially with increasing PD vintage [1–
3]. A potentially relevant issue in PD clearances is the ef-
fect of dialysate temperature on depuration. Indeed, it is
common for clinicians to advise patients in Continuous
Ambulatory Peritoneal Dialysis (CAPD) to warm the di-
alysate before infusion into the peritoneal cavity, with
different methods (microwave oven, warming cabin,
warming pad). Nevertheless, main international PD
guidelines do not provide specific recommendations on
this topic [4, 5]. Only guidelines from the British
Columbia Renal Agency (Canada) [6] dedicate a specific
chapter to the temperature of dialysate, recommending
its warming to 37 °C before peritoneal infusion, mainly
in order to avoid an “uncomfortable lowering of body
temperature”. On the other hand, warming of PD
batches could lead to hot spots formation inside the
batch, especially with microwaves, and to degradation of
glucose leading to the formation of toxic glucose degrad-
ation products (GDPs) [7]. Also, notable differences in
room temperature exist according to geographical lati-
tude and year season, and there are no clear and detailed
reports in the literature regarding intolerable effects of
the infusion of dialysate at room temperature. It must be
acknowledged that it is common practice for patients to
warm dialysate batches only partially or not to warm
them at all. Moreover, warming pads that are most com-
monly used by CAPD patients do not effectively warm
the dialysate up to 37 °C. In our center we recently ob-
served that average dialysate temperature at infusion was
31.1 °C, even if the pad was calibrated to 37 °C [unpub-
lished data]. With respect to the effects on toxins clear-
ances through the peritoneal membrane, a higher
dialysate temperature could theoretically favor vasodila-
tion of peritoneal membrane microcirculation, poten-
tially increasing the passage of substances. Severe
microcirculatory dysfunction has been reported in PD
patients [8] and any intervention designed to ameliorate
microcirculatory flow at peritoneal level could be benefi-
cial. Surprisingly, reports regarding the effects of dialys-
ate temperature on peritoneal clearances in PD in
humans are surprisingly scarce. In 1967 Gross et al. [9]
reported an increase in the exchange of substances be-
tween peritoneal fluid and blood upon warming of the
PD fluid to 37 °C (compared to 20 °C) in a patient
treated with intermittent peritoneal dialysis; the increase
in urea clearance with the 37 °C solution was 35% on
average. In contrast, Indraprasit et al. [10] did not en-
counter differences in peritoneal creatinine clearance
utilizing dialysate at room temperature (27–31 °C) and
warmed at 37 °C in a group of 18 patients in PD.
Confirmation of the effects of dialysate temperature on
peritoneal clearances would be of great interest in order
to maximize the depurative potential of PD and to justify
patients’ effort to warm the batches.
In order to determine the real effects of dialysate
temperature on peritoneal clearances and transport
characteristics, abdominal discomfort and vital signs, we
designed a randomized controlled trial comparing two
strategies of peritoneal dialysate warming.
Methods
Study design and participants
Eighteen PD patients, both in CAPD and automated PD,
in regular follow-up at the Nephrology Unit of the Uni-
versity Hospital of Modena, were randomized to receive
a single dialysis exchange, either with dialysate at a con-
trolled temperature of 37 °C (intervention group) or with
dialysate at warmed with conventional methods at un-
controlled temperature (control group). See Fig. 1 for a
participants flow diagram. Randomization was generated
through the use of the Random Allocation software [11].
Primary end-point of our study was peritoneal creatin-
ine clearance. Secondary end-points were: peritoneal
urea clearance, creatinine and urea dialysate/plasma ra-
tio (D/P), creatinine and urea mass transfer area coeffi-
cient (MTAC), abdominal discomfort, blood pressure
and body temperature.
A power analysis was performed while designing the
study using the few data available in the literature [9,
10]; setting the alpha-error level at 0.05 for a 2-tailed t-
test with a statistical power of 95% (beta-error 0.05) the
estimated sample needed was 14 patients (7 per group).
We thus decided to enroll 9 PD patients per group.
Patients were recruited from September to December
2018; the trial ended when the pre-specified number of
enrolled patients was achieved. The study was conducted
in accordance with the Helsinki Declaration of 1975 (as
revised in 2008) and was approved by the ethical
committee “Comitato Etico dell’Area Vasta Emilia Nord”
of the “Azienda Ospedaliero Universitaria di Modena”
(protocol number: AOU:0018014/18). The trial was regis-
tered at ClinicalTrials.gov (NCT number: NCT04302649).
All study participants received adequate information be-
fore enrollment and signed informed consent. The study
adheres to CONSORT guidelines for reporting clinical tri-
als (see supplementary material).
Inclusion criteria were: age > 18 years and ability to
give informed consent, PD dialysis treatment (either
continuous ambulatory peritoneal dialysis or automated
peritoneal dialysis), PD vintage of more than 3months,
absence of signs of active acute systemic or localized
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infections at least 4 weeks apart from the trial (i.e. peri-
tonitis). Pregnant women were excluded from the study.
Laboratory measurements
Creatinine and urea were measured in plasma, peritoneal
fluid and urine at the Central Laboratory of “Policlinico
di Modena” with the Jaffé and colorimetric methods,
and expressed in mg/dl.
Peritoneal clearances of creatinine and urea were cal-
culated with the following formula:
Cx ¼ Dx½   dialysate volume= Px½ =240
where Cx represents clearance of creatinine or urea
expressed in ml/min, [Dx] represents the concentration
of creatinine or urea in dialysate at the end of the ex-
change (4 h) expressed in mg/dl, dialysate volume repre-
sents the total volume drained at the end of the
exchange (4 h), [Px] represents the concentration of cre-
atinine or urea in plasma after 2 h from the beginning of
the exchange expressed in mg/dl and 240 represents mi-
nutes contained in the 4 h of the exchange.
Data regarding D/P and dialysate volume were also re-
ported separately.
Mass transfer area coefficients (MTAC) for creatinine
and urea were calculated with the RenalSoft software
(converted from the PD Adequest software [12]) from
Baxter Healthcare, Deerfield, IL, U.S.A. Correction for
plasmatic water concentration was not added, since the
main purpose was to compare MTACs from the inter-
vention and control group and not to obtain absolute
data. MTAC is related to the restriction coefficient
for a specific solute through a double logarithmic
scale. Variations of the MTAC of a small solute are
mainly caused by variation in the vascular surface
area, and thus the number of available pores. A rise
in MTAC indicates an increase in the number of
available pores and vice versa [13].
Urinary clearances of creatinine and urea were calcu-
lated with the following formula:
Cx ¼ Ux½   urine volume= Px½ =240
where Cx represents clearance of creatinine or urea
Fig. 1 Study flow diagram
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expressed in ml/min, [Ux] represents the concentration
of creatinine or urea in urine at the end of the exchange
(4 h) expressed in mg/dl, urine volume represents the
total volume collected at the end of the exchange (4 h),
[Px] represents the concentration of creatinine or urea
in plasma after 2 h from the beginning of the exchange
expressed in mg/dl and 240 represents minutes con-
tained in the 4 h of the exchange. Patients were required
to empty their bladder before the exchange.
Blood pressure was measured hourly during the ex-
change with an automatic sphygmomanometer and
expressed in mmHg.
Body temperature was measured hourly during the
exchange with an auricular thermometer and
expressed in °C.
Abdominal discomfort was monitored through specific
questions to the patient hourly during the exchange and
through the administration of a specific questionnaire at
the end of the exchange. The abdominal discomfort
questionnaire was adapted from Figueiredo et al. [14],
and contained 7 specific questions regarding the appear-
ance of the following symptoms during or immediately
after the exchange: chills, vomiting, abdominal pain, ab-
dominal distension, constipation, diarrhea, loss of appe-
tite. Every symptom was graded by the patient from 0 to
3 according to its intensity, and a total score for every
patient was elaborated (range 0–21 points).
Peritoneal exchange performance
All patients received an in-hospital 4 h Peritoneal Equili-
bration Test (PET) performed by nurses trained in the
PD dialysis service of the Nephrology Unit of the Uni-
versity Hospital of Modena. The PET, originally pro-
posed by Twardowski [15, 16], consists of a 4 h
exchange with 2 l of peritoneal dialysate at a glucose
concentration of 2.27% where plasma and dialysate con-
centration of creatinine and glucose are assessed at dif-
ferent time points during the test; the PET can be used
to calculate peritoneal clearances and MTACs of cre-
atinine and urea with the above mentioned formulas.
Patients received PET with dialysate at 37 °C or at un-
controlled temperature, according to randomization. In
the intervention group, dialysate was warmed in a spe-
cific microwave oven calibrated to 37 °C and infusion
temperature was confirmed to be 37 °C before infusion.
In the control group, current practice was used (batch
warming with a pad calibrated to 37 °C) and dialysate
temperature was measured just before infusion.
All temperature measurements were performed with
an infrared thermometer and expressed in °C.
A sample of peritoneal dialysate was drained and sent
for analysis at the beginning of the test and at 2 and 4 h;
the total amount of fluid drained at the end of the test
was measured. A blood sample was drawn at 2 h from
the beginning of the test and sent for analysis. The
amount of urine produced during the 4 h test was mea-
sured and a sample sent for analysis.
Blood pressure and body temperature were monitored
during the PET as previously described.
Statistical analysis
Continuous data are presented as mean and standard
error of the mean; discrete data are presented as propor-
tions. Continuous variables were compared with Stu-
dent’s t-test (two tailed). Proportions were compared
with Fisher’s exact test. A p value lower than 0.05 was
considered statistically significant. Statistical analysis was
performed with GraphPad Prism software version 7.00
for Windows, GraphPad Software, La Jolla California
USA, www.graphpad.com.
Results
Characteristics of the intervention and control groups
are reported in Table 1. As expected, there was a statisti-
cally significant difference in dialysate temperature be-
tween the intervention and control group (36.78 ±
0.38 °C vs 32.22 ± 0.26 °C, respectively, p < 0.0001). Other
relevant patient characteristics were not significantly dif-
ferent between the two groups. Specifically, there were
the same proportions of males, diabetics, hypertensive,
high average peritoneal transporters and the two groups
did not differ in age, PD vintage, residual urinary output,
urinary creatinine clearance; moreover, main laboratory
blood tests (including serum albumin and C-reactive
protein) were similar between the two groups.
Patients in the intervention group did not show a
higher peritoneal creatinine clearance when compared to
patients in the control group (6.38 ± 0.52ml/min vs
5.65 ± 0.37 ml/min, p = 0.2682), as depicted in Fig. 2. In
accordance with this result, we encountered no differ-
ence in urea peritoneal clearance (8.28 ± 0.31 ml/min in
the intervention group vs 8.92 ± 0.45 ml/min in the con-
trol group, p = 0.2561); see Fig. 3. As a further confirm-
ation, the two groups did not differ significantly for
creatinine D/P (0,72 ± 0.18 in the intervention group vs
0,61 ± 0,14 in the control group, p = 0,1846), urea D/P
(0.92 ± 0.07 in the intervention group vs 0,95 ± 0.12ml/
min in the control group, p = 0.5718) and drained dialys-
ate volume (2156 ± 212,8 ml in the intervention group
vs 2267 ± 325 ml in the control group, p = 0.4035)
(Fig. 4). In addition, MTACs for creatinine and urea
were not different between the two groups (MTAC cre-
atinine 10.66 ± 1.77 ml/min in the intervention group
and 8.82 ± 1.08 ml/min in the control group, p = 0.3781;
MTAC urea 22.05 ± 1.69 ml/min in the intervention
group and 22.66 ± 2.03 ml/min in the control group,
p = 0.8199); see Fig. 5.
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Patients showed very few abdominal symptoms and
there were no significant differences in the total abdom-
inal discomfort questionnaire score between the two
groups (see Table 2). Blood pressure and body
temperature at different time points were also
comparable between the two treatment dialysate temper-
atures, as reported in Table 2.
Discussion
In the present study, we found no differences on peri-
toneal clearances of small molecules in a PET using di-
alysate at two different temperatures; also, no differences
in abdominal discomfort and vital signs were noted.
Available literature data do not univocally determine
the role of dialysate temperature with respect to periton-
eal clearances, neither clear data exists about the occur-
rence of local or systemic side effects with different
dialysate temperatures. Theoretically, an increase in
temperature in the peritoneal cavity could lead to an in-
crease in microcirculatory vasodilation at the local level,
increasing the total pore area, in contrast to what would
happen using cooler dialysis fluid. The contact with a
warmer dialysis fluid could enhance the increase in
blood flow (usually occurring at the start of the dialysis
dwell), and hyperemia could have an important impact
on solute transport [17].
Gross et al. [9] previously compared peritoneal urea
clearance several times in one patient, comparing dialys-
ate warmed at 37 °C with that infused at 20 °C. They re-
ported a urea clearance that was 35% higher with the
former compared to the latter. Unfortunately, their re-
sults are of scarce utility because a dialysate temperature






n. patients 9,00 9,00
dialysate temperature (°C) 32,22 ± 0,26 36,78 ± 0,38 < 0,0001
males (percentage) 78% 78% ns
diabetics (percentage) 22% 56% ns
hypertensive (percentage) 89% 89% ns
high average transporters (percentage) 44% 44% ns
low average transporters (percentage) 33% 44% ns
high transporters (percentage) 0% 11% ns
low transporters (percentage) 22% 0% ns
dialysis vintage (months) 28,44 ± 9,11 25,56 ± 5,82 ns
urinary creatinine clearance (ml/min) 4,72 ± 2,76 6,32 ± 2,01 ns
urine output (ml/4 h PET test) 133,30 ± 72,65 188,90 ± 54,50 ns
dialysate volume drained (ml) 2267,00 ± 108,30 2156,00 ± 70,93 ns
serum creatinine (mg/dl) 9,53 ± 1,23 8,39 ± 0,79 ns
serum urea (mg/dl) 110,10 ± 8,55 118,00 ± 11,84 ns
serum albumin (g/dl) 3,70 ± 0,11 3,42 ± 0,13 ns
serum hemoglobin (g/dl) 11,60 ± 0,00 11,42 ± 0,36 ns
serum c-reactive protein (mg/dl) 0,29 ± 0,06 0,63 ± 0,28 ns
Data are presented as mean ± standard error of the mean (SEM) or percentages
ns non-significant
Fig. 2 Peritoneal creatinine clearance in the uncontrolled dialysate
temperature group (light grey bar) and 37° dialysate temperature
group (dark grey bar)
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of 20 °C is extremely lower than that used in clinical
practice, in almost every setting. Moreover, their data
come from seriate analysis in the same single patient.
On the contrary, in an observational case-control
study performed in Thailand, Indraprasit et al. [10]
encountered no differences in peritoneal urea, creatin-
ine and inulin clearances treating the patients with di-
alysate first at room temperature and then warmed
up to 37 °C.
We performed a randomized study in order to ascer-
tain the potential beneficial effects of higher dialysate
temperature on peritoneal toxins clearances.
As can be judged by the results presented in Table 1,
intervention and control groups were significantly differ-
ent with respect to dialysate temperature at infusion and
very well balanced for patients’ characteristics. Specific-
ally, we encountered no differences in the proportions of
males, diabetic patients and high-average peritoneal
Fig. 3 Peritoneal urea clearance in the uncontrolled dialysate temperature group (light grey bar) and 37° dialysate temperature group (dark
grey bar)
Fig. 4 Dialysate to plasma ratio for creatinine and urea (left and middle panel, left y axis) and dialysate drained volume (right panel, right y axis)
for the uncontrolled dialysate temperature group (light grey bar) and 37° dialysate temperature group (dark grey bar)
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transporters, all factors that could have an influence on
peritoneal clearances of toxins.
Treatment with dialysate at 37 °C failed to meet the
primary end-point of superior peritoneal creatinine
clearance compared to current clinical practice. More-
over, also urea peritoneal clearance, D/P for creatin-
ine and urea, and peritoneal MTACs for urea and
creatinine were not different between intervention
and control groups.
We believe that the reasons for these relatively unex-
pected results can be related to the shortness of the
temperature effects on microcirculation and to the influ-
ence of factors other than blood flow transport in small
solutes peritoneal clearances.
Indeed, the vasoconstrictive effects of a lower
temperature dialysate can be as brief as the first half
hour of an exchange [17]. Since peritoneal dialysis
temperature is rapidly equilibrated with body
temperature, the potential effect of an initial lower di-
alysate temperature on toxin clearance is very difficult to
ascertain in a 4 h PET. Moreover, blood flow is thought
to have little (if any) effect on solute transport through
the peritoneal membrane, and the effect of capillary ex-
change events on total transperitoneal transport is prob-
ably lower than expected due to the action of peritoneal
interstitium, which is critical in the transport of small
solutes [17]. Waniewski et al. [18] reported a 5–6 fold
increase in the superficial peritoneal blood flow during
the initial part of an ordinary peritoneal dialysis dwell in
their mathematical PD model; nevertheless, the overall
impact of this hyperemia on the measured creatinine
flux was only approximately 60%, due to the impact of
the interstitium, coupled in series with the capillaries,
which critically modifies the overall peritoneal transport
of small solutes. In addition, it is known that peritoneal
dialysis fluids possess intrinsic vasodilator properties,
Fig. 5 Peritoneal mass transfer urea coefficients (MTAC) for creatinine (left panel) and urea (right panel) in the uncontrolled dialysate temperature
group (light grey bars) and 37° dialysate temperature group (dark grey bars)
Table 2 Secondary outcomes in the control (uncontrolled T) and intervention (37 °C T) groups
Uncontrolled T 37 °C T p value
Abdominal discomfort questionnaire (points) 0.38 ± 0.38 0.11 ± 0.11 ns
Mean arterial pressure t0 (mmHg) 102.8 ± 3.29 99.22 ± 5.01 ns
Mean arterial pressure t1 (mmHg) 97.33 ± 2.89 100.9 ± 3.86 ns
Mean arterial pressure t2 (mmHg) 97.93 ± 3.33 98.93 ± 4.09 ns
Mean arterial pressure t3 (mmHg) 98.41 ± 3.15 93.04 ± 3.11 ns
Mean arterial pressure t4 (mmHg) 97.37 ± 3.35 99.15 ± 5.78 ns
Body temperature t0 (°C) 35.56 ± 0.28 35.88 ± 0.32 ns
Body temperature t1 (°C) 35.57 ± 0.23 35.87 ± 0.26 ns
Body temperature t2 (°C) 35.67 ± 0.23 35.78 ± 0.17 ns
Body temperature t3 (°C) 35.86 ± 0.19 35.86 ± 0.17 ns
Body temperature t4 (°C) 35.86 ± 0.17 35.9 ± 0.17 ns
Continuous data are expressed as mean ± standard error of the mean (SEM). ns non-significant; t0, t1, t2, t3, t4 = measurements at 0, 1, 2, 3, 4 h from the
beginning of the exchange
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mediated by endothelium-dependent mechanisms that
primarily involve hyperosmolality [19, 20]. Vasodilation
enhances small solutes and fluid transport, and typically
occurs during the initial phase of a peritoneal dwell [21,
22], making difficult to ascertain a pure effect of dialys-
ate temperature on peritoneal clearances.
In our study, patients in both groups reported a very
low rate of side effects. Specifically, scores of the abdom-
inal discomfort questionnaire were almost null, and did
not differ between the groups. Warming peritoneal di-
alysate to 37 °C appeared to have no significant effects
on blood pressure and body temperature during the
PET. These data should reassure clinicians that periton-
eal dialysate can be used at different temperatures with-
out causing significant side effects or discomfort to
patients.
Maintaining a high and constant dialysate temperature
before infusion at every PD exchange is a time-
consuming process that should be justified by a potential
increase in depurative effects or the correction of symp-
toms that could appear with lower dialysate temperature.
Also, in the era where portable and wearable PD devices
are under development, it is very important to define
whether a specific dialysate temperature should be ad-
dressed to avoid unnecessary challenges for the design
that could hamper miniaturization.
In our study a higher dialysate temperature failed to
provide evidence for superior peritoneal clearance of
small molecules compared to common clinical practice
at our center. We believe that any effort to rise dialysate
temperature with the goal of increasing peritoneal
depuration is not supported by evidence.
Future guidelines for PD should consider that evidence
towards a recommendation for PD fluid warming to
37 °C is totally lacking.
Our study has some limitations. We acknowledge that
the two ranges of dialysate temperature tested were rela-
tively high and close to each other. As previously stated,
the present study was intended as explorative; in
addition, further lowering dialysate temperature in the
control group was considered unfeasible due to ethical
concerns and the theoretical risk of abdominal symp-
toms and hypothermia.
In addition, the study is monocentric and we included
a relatively low number of PD patients for a single 4 h
PET, limiting the generalization of our results in the
long term. We enrolled a relatively low number of pa-
tients, for two main reasons. First, this was meant to be
an explorative study, which could potentially have been
expanded in case of problems with the randomization
process. Second, the power analysis we performed before
starting the study estimated a sample size of 7 patients
per group (which we decided to increase to 9 per group)
to achieve a statistical power of 95%, as stated above.
Furthermore, the lack of a cross-over design in our
study could not account for possible interpatient
differences generally existing among peritoneal func-
tional behaviors. Nevertheless, we also consider that
randomization of the present study adds strength to our
findings.
Lastly, our study was not designed to assess the long-
term effects of dialysate warming on peritoneal function.
Since some patients reported very little adherence to
dialysate warming practice during their exchange
routine, a further study designed to compare current
practice with a lower dialysate temperature could be per-
formed in the future.
Conclusions
We report the results of a randomized controlled study
assessing the effects of peritoneal dialysate temperature
on peritoneal clearance of creatinine. Patients random-
ized to a peritoneal dialysate temperature of 37 °C did
not show an increased creatinine peritoneal clearance
during a 4 h PET when compared to patients treated
with dialysate at uncontrolled temperature (around
32 °C). In addition, peritoneal clearance of urea and peri-
toneal transport of creatinine and urea did not differ
between the groups. In both groups the incidence of ab-
dominal discomfort was very low and dialysate
temperature had no influence on blood pressure and
body temperature. We believe that the potential increase
in peritoneal microcirculatory blood flow related to the
exposure to higher temperature (when compared with
standard temperature) is too short to significantly en-
hance peritoneal small solute transport. The effect is
probably further limited by the influence of the periton-
eal interstitium. Clinicians should inform patients about
the lack of benefit of warming peritoneal dialysate to
37 °C and future PD guidelines should not reinforce this
recommendation.
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